Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pancrelipase versus placebo for pancreatic exocrine insufficiency in type 2 diabetes
ACTRN12617000349347Phase 4Not yet recruiting
- Sponsor
- University of Adelaide
- Start
- Mar 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of pancrelipase in exocrine pancreatic insufficiency (EPI) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University of Adelaide. Primary endpoint: Postprandial hyperglycaemia. Planned start Mar 2017; status: not yet recruiting.
02
Drugs
pancrelipase
03
Conditions
exocrine pancreatic insufficiency (EPI)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12617000349347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000349347.